Long-term bisphosphonate in breast cancer ‘provides no extra benefit’
It may be time to question the role of the bone-sparing therapy, say expert commentators.
It may be time to question the role of the bone-sparing therapy, say expert commentators.
One in four patients show reactivity on PET scans that could lead to cancer misdiagnosis, researchers report.
Surgical data suggest more than a third of women with the condition are having the procedure.
The potential danger for patients with breast or prostate cancer must not be overlooked, expert says.
The antibody-drug conjugate is being fast-tracked to market because of its promise for patients with few other treatment options.
The effect is strongest in the five years postsurgery, Canadian investigators report.
A study of half a million women underscores the benefit of participating in a screening program, researchers say.
It helps to have good information and a surgeon who backs their decision, survey shows.
A Swedish registry study sheds light on how risk varies depending on family history.
In a subgroup of patients, biopsy can reliably predict a complete response to neoadjuvant therapy, researchers say.
Â
Â
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.